Wedbush Maintains Outperform on Disc Medicine, Lowers Price Target to $88

Disc Medicine, Inc. +2.95% Pre

Disc Medicine, Inc.

IRON

70.48

70.48

+2.95%

0.00% Pre
Wedbush analyst David Nierengarten maintains Disc Medicine (NASDAQ: IRON) with a Outperform and lowers the price target from $110 to $88.